Jan. 9, 2023—Nashville Biosciences LLC, a wholly owned subsidiary of Vanderbilt University Medical Center, and Illumina Inc., a global leader in DNA sequencing and array-based technologies, today announced an agreement with Amgen, a global biopharmaceutical company, to whole-genome sequence approximately 35,000 DNA samples.
Dec. 8, 2022—Vanderbilt researchers have developed a framework for the analysis of multiancestry, large-scale genomic studies across multiple biobanks.
Vanderbilt biostatisticians launch Cancer-Immu data portal for predicting response to immune checkpoint blockade immunotherapy
Jan. 14, 2022—A new data portal called Cancer-Immu established by a team of Vanderbilt University Medical Center biostatisticians can help cancer clinicians and researchers predict which patients will respond to immune checkpoint inhibitors.
Nashville Biosciences and Illumina announce agreement to establish preeminent clinico-genomic resource for life sciences research & development
Jan. 10, 2022—Nashville Biosciences, a wholly-owned subsidiary of Vanderbilt University Medical Center, has announced an agreement with Illumina, a leading genomic technology company, to realize the full potential of VUMC’s DNA databank, BioVU.
Oct. 18, 2021—Roland Eils, PhD, will discuss efforts to translate the deluge of genomics data generated by international initiatives into understanding disease mechanisms during the next web-based Discovery Lecture.
Sep. 10, 2020—Eric Gamazon, PhD, assistant professor of Medicine, has been awarded a $1.5 million grant from the National Human Genome Research Institute, part of the National Institutes of Health (NIH), to develop novel computational tools that integrate functional genomic data and electronic health records.
Jul. 1, 2020—With the aid of a $75 million, five-year grant renewal, the Electronic Medical Records and Genomics Network (eMERGE) will venture beyond its current focus on monogenic disease to scoring research participants’ relative risk for complex heritable diseases such as cardiovascular disease, chronic kidney disease and type 2 diabetes.
Nov. 7, 2019—Vanderbilt-Ingram Cancer Center is one of three institutions launching the first phase of a collaboration to advance precision oncology through the creation of a clinico-genomic dataset with an international reach.
Oct. 11, 2018—Loss of a protein that regulates mitochondrial function can greatly increase the risk of myocardial infarction (heart attack), Vanderbilt scientists reported Oct. 3 in the journal eLife.
Apr. 20, 2018—The Center for Genetic Privacy and Identity in Community Settings (GetPreCiSe) at Vanderbilt University Medical Center has set its annual workshop exploring privacy and genomics for April 30.